Remdesivir

Remdesivir.svg

Remdesivir is an antiviral drug developed by the biopharmaceutical company Gilead Sciences. It is a nucleotide analog, specifically an adenosine analog, which interferes with the action of viral RNA-dependent RNA polymerase and has broad-spectrum antiviral activity against several RNA viruses.

Development and Mechanism of Action

Remdesivir was originally developed to treat Ebola virus infections. However, it showed limited efficacy in clinical trials for Ebola. The drug works by inhibiting the RNA-dependent RNA polymerase enzyme, which is essential for the replication of RNA viruses. By incorporating into the viral RNA chain, remdesivir causes premature termination of the RNA transcription process, thereby inhibiting viral replication.

Clinical Use

Remdesivir gained significant attention during the COVID-19 pandemic as a potential treatment for SARS-CoV-2, the virus responsible for COVID-19. Clinical trials have shown that remdesivir can reduce the time to recovery in hospitalized patients with severe COVID-19. It was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) in May 2020 and later received full approval in October 2020.

Administration and Dosage

Remdesivir is administered intravenously. The typical dosage regimen for COVID-19 involves a loading dose followed by daily maintenance doses. The duration of treatment can vary depending on the severity of the disease and the patient's response to the medication.

Side Effects and Safety

Common side effects of remdesivir include nausea, elevated liver enzymes, and potential allergic reactions. It is important to monitor liver function during treatment. The safety and efficacy of remdesivir in certain populations, such as pregnant women and children, are still under investigation.

Regulatory Status

Remdesivir has been approved or authorized for emergency use in several countries around the world. Its approval status may vary depending on the regulatory framework of each country.

Research and Future Directions

Ongoing research is exploring the use of remdesivir in combination with other antiviral or anti-inflammatory agents to enhance its efficacy against COVID-19 and other viral infections. Studies are also being conducted to evaluate its potential use in treating other RNA virus infections.

See Also

• Antiviral drug
• COVID-19 pandemic
• SARS-CoV-2
• RNA-dependent RNA polymerase
• Gilead Sciences

External Links

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian